Researchers tout 'biological pacemaker'; Isis takes to Phase II with novel cardio drug;

@FierceBiotech: Alkermes takes its Tecfidera beater into clinical trials for MS. News | Follow @FierceBiotech

@DamianFierce: Has anyone run the numbers to determine the biggest stock-moving news possible? Cutting jobs + moving to Ireland + buying ultra-rare drug? | Follow @DamianFierce

@EmilyMFierce: 'Biological pacemaker' restores heartbeat in pigs. FierceBiotech Research article | Follow @EmilyMFierce

> Researchers have discovered a gene therapy treatment that could replace the need for a pacemaker in patients with heart rhythm disorders. News

> Isis Pharmaceuticals ($ISIS) has kicked off a Phase II study for a treatment designed to attack a lipoprotein particle tied to coronary heart disease and heart attack. More

> Gingko Bioworks, the first biotech backed by startup factory Y Combinator, is working to develop treatments for antibiotic-resistant germs. Story

Medical Device News

@FierceMedDev: FDA rejects petition to ban transvaginal mesh. Article | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Food resembling human organs was once considered a remedy for disease, but the "Doctrine of Signatures" falls short. Wired story | Follow @EmilyWFierce

> Amid positive Q2 sales, St. Jude looks to renal denervation as untapped niche. Report

> Danaher adds to its diagnostics biz, but deal may not be large enough for the Street. Story

> UPS ramps up delivery service for medical device industry. More

> Medtronic could face legislative pushback in tax-inversion deal with Covidien. Article

Pharma News

@FiercePharma: Tops on FiercePharmaMarketing: Afraid of aging? Pfizer's revamped 'Get old' campaign wants you. Item | Follow @FiercePharma

@TracyStaton: $GSK just can't escape China questions. Ex-workers sue, news of 2001 corruption breaks. More | Follow @TracyStaton

@EricPFierce: Baxter is recalling three lots of saline in the midst of the of the U.S. shortage. FDA recall notice | Follow @EricPFierce

@CarlyHFierce: ICYMI: this week's issue of FiercePharmaMarketingReport | Follow @CarlyHFierce

> Salix scores another FDA green light with approval for angioedema med Ruconest. Item

> Novartis sales flag on Diovan generics, but CEO promises cost cuts will fuel profits. More

> Arkansas stiff-arms CF patients seeking Vertex's $300K drug Kalydeco: WSJ. Story

> Novartis offloads share of LTS Lohmann to SAP billionaire Hopp, gaining $400M. Article

Vaccines News

> Germany's immatics bags $30M for cancer vaccine trial. Article

> Extra dose of inactivated polio vaccine provides greater protection in children. More

> Microbix sues Novartis for patent infringement in Europe. Item

> Novartis' soon-to-be-Glaxo's vax unit sees mounting losses, diving sales in Q2. Story

> As Glaxo begins '14-'15 flu vaccine shipments, manufacturing questions linger. Article

Pharma Manufacturing News

> Aptuit putting $1M into cytotoxic capabilities in Scotland. Item

> GSK recalls acetaminophen products that were not child-proofed. More

> Baxter issues global recall of saline in midst of U.S. shortage. News

> J&J improves McNeil unit sales even as key plant remains closed for remediation. Story

> Pfizer and Sun snatch up sterile injectable companies to boost expertise and capacity. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.